BAQSIMI Adverse Reactions in Pediatric Patients
Adverse reactions (%) occurring in pediatric patients with an incidence of ≥5%
Adverse Reactions
|
BAQSIMI 3 mg (n=36) %
|
INJECTABLE GLUCAGON (weight based) (n=24) %
|
---|---|---|
Adverse Reactions Gastrointestinal disorders | BAQSIMI 3 mg (n=36) % | INJECTABLE GLUCAGON (weight based) (n=24) % |
Adverse Reactions Vomiting | BAQSIMI 3 mg (n=36) % 30.6 | INJECTABLE GLUCAGON (weight based) (n=24) % 37.5 |
Adverse Reactions Nausea | BAQSIMI 3 mg (n=36) % 16.7 | INJECTABLE GLUCAGON (weight based) (n=24) % 33.3 |
Adverse Reactions General disorders and administration site conditions | BAQSIMI 3 mg (n=36) % | INJECTABLE GLUCAGON (weight based) (n=24) % |
Adverse Reactions Injection site discomfort | BAQSIMI 3 mg (n=36) % 0 | INJECTABLE GLUCAGON (weight based) (n=24) % 20.8 |
Adverse Reactions Nervous system disorders | BAQSIMI 3 mg (n=36) % | INJECTABLE GLUCAGON (weight based) (n=24) % |
Adverse Reactions Headache | BAQSIMI 3 mg (n=36) % 25.0 | INJECTABLE GLUCAGON (weight based) (n=24) % 12.5 |
Adverse Reactions Respiratory, thoracic and mediastinal disorders | BAQSIMI 3 mg (n=36) % | INJECTABLE GLUCAGON (weight based) (n=24) % |
Adverse Reactions Nasal discomfort | BAQSIMI 3 mg (n=36) % 8.3 | INJECTABLE GLUCAGON (weight based) (n=24) % 0 |
Adverse Reactions Nasal congestion | BAQSIMI 3 mg (n=36) % 5.6 | INJECTABLE GLUCAGON (weight based) (n=24) % 0 |